AUTHORS
Fatima Bansiradj, MD, Anoosha Habibi, MD/ Associated Professor2, Yosr Zaouali3, Hamza Sakhi, MD4, Thomas D'Humières, MD5, Pablo Bartolucci, MD, PhD6, Vincent Audard7
AFFILIATIONS
1 HENRI MONDOR HOSPITAL AP-HP, Créteil, France
2 HENRI MONDOR HOSPITAL AP-HP, Créteil, France
3 HENRI MONDOR HOSPITAL AP-HP, Créteil, France
4 Hôpitaux Universitaires Henri Mondor, Assistance Publique-Hôpitaux de Paris, Université Paris Est Créteil., Créteil, Île-de-France, France
5 HENRI MONDOR HOSPITAL AP-HP, Créteil, France
6 HENRI MONDOR HOSPITAL AP-HP, Créteil, France
7 Hôpitaux Universitaires Henri Mondor, Assistance Publique-Hôpitaux de Paris, Université Paris Est Créteil., Créteil, Île-de-France, France
ABSTRACT
Background:Over the past several years,the clinical landscape of chronic kidney disease (CKD) has been fundamentally reshaped by the introduction of sodium-glucose cotransporter 2 inhibitors (SGLT2i).Given the need for novel disease-modifying therapies to slow kidney function decline in sickle cell disease(SCD),SGLT2i represent a promising therapeutic strategy in this population.However,the use of SGLT2i in SCD requires careful evaluation because of the specific pathophysiology of the disease,including chronic hemolysis,endothelial dysfunction,and recurrent vaso-occlusive crisis(VOC).The osmotic diuretic effects of SGLT2i may increase the risk of volume depletion and hemoconcentration in SCD patients.On the other hand,SGLT2i are known to increase hemoglobin(Hb) and hematocrit(HTC) levels,potentially reflecting expansion of the erythroid compartment.The impact of these effects on blood volume regulation and blood viscosity in SCD remains unknown.Therefore,we evaluated the effects of Dapagliflozin on hematological parameters and blood volume dynamics in patients with SCD,to assess its safety profile and its potential role in the management of SCD-associated nephropathy.
Methods:We conducted a prospective,observational study at sickle cell referral center(Henri Mondor Hospital). Adult patients(≥18 years) with SCD-related nephropathy receiving stable angiotensin–converting enzyme inhibitor[ACEi] or angiotensin II receptor blocker[ARB] therapy,with an estimated glomerular filtration rate(eGFR) between 35-75mL/min/1.73 m² and a urinary albumin to creatinine ratio(UACR) between 20-500mg/mmol,received Dapagliflozin 10mg daily for 12 months.The study was initially designed to evaluate renal outcomes and safety(results previously reported).Were also assessed hemoglobin mass and blood volume compartments using a standardized carbon monoxide rebreathing protocol.In addition,hematological parameters,blood viscosity, hemolysis markers,and erythropoietin levels were evaluated.
Results:16 predominantly HbSS (88%) patients,(median age 53 [IQR:45.5- 61],56% female), including 15 receiving hydroxyurea, were initially enrolled.10 patients completed the M12 follow-up. Among them,3 were receiving erythropoietin (EPO) therapy,one was enrolled in a chronic exchange transfusion program,and one patient receiving both therapies. Diuretic treatment was adjusted in 4 patients.In the overall cohort(N=10), Dapagliflozin was associated with increases in total blood volume from 7.65L [IQR: 5.45-8.81] at baseline to 8.24L [IQR:8.04-10.11] at M12(p=0.313), plasma volume, from 5.82L [IQR:4.03-6.69] to 6.31L [IQR:5.64-7.11],(p=0.313), red cell volume,from 1.84L [IQR:1.4-2.36] to 2.47L [IQR:2.13-3.15],(p=0.219), and hemoglobin mass,from 619 g [IQR:491-825] to 852 g [IQR:739-1045],(p=0.219). Hematocrit (HCT) increased significantly from 25% [IQR:23.3-27.8] to 27% [IQR:25-30.8],(p=0.020). Despite these changes,Hb concentration slightly increased from 8.8 g/dL [IQR:8.1-9.7] at baseline to 9 g/dL [IQR:8.4-10.2], (p=0.027),suggesting partial compensation by plasma volume expansion. Blood viscosity (BV) increased from 4.54cP [IQR:4.33-4.81] to 5.44cP [IQR:4.77-6.41],but did not reach statistical significance(p=0.313).
These findings were also observed in the subgroup of patients not receiving EPO and/or chronic transfusion therapy (N=5).Hb increased from 8.2 g/dL [IQR:8.1-9.8] to 9.3g/dL [IQR:8.6-11.2],(p=0.125).HCT increased from 24% [IQR:23.7-28] to 28% [IQR:25-32],(p=0.109),while BV increased from 4.28cP [IQR:3.85-4.45] to 5.7cP [IQR:4.86-6.7],(p=0.25).None of these changes reached statistical significance,probably due to the limited sample size.Analysis of plasma EPO levels and hemolysis markers is currently ongoing.
Regarding VOCs,3 patients experienced a total of 4 VOC episodes during follow-up (occurring at months 3,5,9,and 11), compared with 2 VOC episodes recorded during the year preceding Dapagliflozin initiation.
Conclusion: The 12-month data,show that Dapagliflozin was associated with a significant increase in HCT, whereas increases in blood volume parameters,Hb concentration, and blood viscosity were observed as trends,in patients with SCD-related nephropathy.While concomitant plasma volume expansion appeared to prevent clinically relevant hemoconcentration.Given the limited sample size and potential confounding effects of concomitant therapies,larger studies are needed to confirm these findings and assess the risk of vaso-occlusive complications.
DISCLOSURES
Fatima Bansiradj, MD: No relevant conflicts of interest to declare.